When was RiboTask founded?

RiboTask was founded in 2006 and raised its 1st funding round within a year of its incorporation.

Where is RiboTask located?

RiboTask is headquartered in Langeskov, Denmark.

Which legal entities is RiboTask associated with?

RiboTask is associated with RIBOHOLDING ApS and 1 other.

How many employees does RiboTask have?

As of Dec 31, 2021, the latest employee count at RiboTask is 1.

Is RiboTask a funded company?

RiboTask is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Aug 29, 2006.

When was the latest funding round of RiboTask?

RiboTask's latest funding was a $***** Seed round on Aug 29, 2006, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. Globally, the Life Sciences Platforms and Tools sector has seen $2.51B in funding in 2026 to date.

Where does RiboTask rank among its competitors?

RiboTask ranks 379th amongst 376 active competitors, of which 48 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was OliX Pharmaceuticals, which secured $72.7M in Jun, 2026.

Who are the top competitors of RiboTask?

RiboTask's top competitors include Orna, Enzo and Parse Biosciences. Among them, OliX Pharmaceuticals secured the most recent funding round in June, 2026.

RiboTask - 2026 Company Profile, Team, Funding, Competitors & Financials

RiboTask is a seed company based in Langeskov (Denmark), founded in 2006 by Jesper Wengel and Suzy Wengel. It operates as a Develops LNA-modified RNA oligonucleotides, RNAi and microRNA research applications;. RiboTask has raised an undisclosed amount in funding. The company has 376 active competitors, including 48 funded and 63 that have exited. Its top competitors include companies like Orna, Enzo and Parse Biosciences.

Company Details

RiboTask is a Danish biotechnology company offering RNA oligonucleotides for research and development purposes. Among the products and services provided by RiboTask are highly complex RNA oligonucleotides and incorporation of customer-specific proprietary modifications. Central products of RiboTask are UNA- and LNA-modified RNA oligonucleotides, and "Superior-Probes" for microRNA targeting. RiboTask is furthermore engaged in research and development of new RNA-related products and technologies.

Website: www.ribotask.com/
Social
Email ID: *****@ribotask.com

Key Metrics

Founded Year

2006

Location

Langeskov, Denmark

Stage

Seed

Latest Funding Round

Seed, Aug 29, 2006, $*****

Investors

Science Ventures

Ranked

379^th among 456 competitors

Employee Count

1 as on Dec 31, 2021

Similar Companies

Orna & 67 more

View RiboTask's full profile

RiboTask is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
RIBOTASK ApS CIN: 29789983 , Denmark, Active	Aug 16, 2006	-	2 (As on Mar 31, 2024)
RIBOHOLDING ApS CIN: 29835772 , Denmark, Active	Dec 31, 2005	-	-

RiboTask has raised funding over 1 round. Its latest funding round was a Seed round on Aug 29, 2006 for $*****. 1 investor participated in its latest round. RiboTask has 1 institutional investor.

Here is the list of recent funding rounds of RiboTask:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 29, 2006	4749491	Seed	5902842	9220729	6028959	5083010

Access funding benchmarks and valuations. Sign up today!

View details of RiboTask's funding rounds and investors

The founders of RiboTask are Jesper Wengel and Suzy Wengel. Suzy Wengel is the CEO of RiboTask.

Here are the details of RiboTask's key team members:

Jesper Wengel: Co-Founder & Chairman of RiboTask. They serve on the board of 1 company.
Contact Info: 1 email address
Suzy Wengel: Co-Founder & CEO of RiboTask. They serve on the board of 1 company.

RiboTask's Board of Directors

RiboTask's board has 2 active members. Jesper Wengel and Suzy Wengel are part of team.

Here is the list of RiboTask's board of directors:

Name	Type	Representing	Status	Duration
Jesper Wengel	Team	-	Current	20y 0m
Suzy Wengel	Team	-	Current	20y 0m

View details of RiboTask's Founder profiles and Board Members

RiboTask's employee count trend

RiboTask has 1 employees as of Dec 21. The total employee count is the same as what it was in Dec 20. Here is RiboTask's employee count trend over the years:

Uncover RiboTask's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RiboTask include Orna, Enzo and Parse Biosciences. Here is the list of Top 10 competitors of RiboTask, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Orna 2020, Cambridge (United States), Acquired	Developer of technologies for producing circular RNA therapeutics	$201M	F2 Ventures, Taiho Ventures & 7 others	67/100
2nd	Enzo 1976, Farmingdale (United States), Acquired	Life science products and services for research, drug discovery, and manufacturing	$7M	-	65/100
3rd	Parse Biosciences 2018, Seattle (United States), Series C	Developer of RNA-sequencing solution-based transcriptome kit to analyze health data	$100M	Marshall Wace, Janus Henderson Investors & 8 others	64/100
4th	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	Qiming Venture Partners, CTS Capital & 1 others	63/100
5th	Rznomics 2017, Yongin si (South Korea), Public	Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology	$48.7M	QUAD, Korea Development Bank Europe & 13 others	62/100
6th	Devyser 2004, Stockholm (Sweden), Public	Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders	$15.5M	Swedbank Robur, Fjarde AP-fonden & 1 others	61/100
7th	OliX Pharmaceuticals 2010, Suwon-si (South Korea), Public	Developer of RNAi therapeutics for dermal, ophthalmic and pulmonary diseases.	-	IMM Investment, Weiss Asset Management & 16 others	61/100
8th	Dicerna Pharmaceuticals 2007, Lexington (United States), Acquired	Developer of drugs by using RNA interference technology platform	$106M	RA Capital Management, Domain Associates ... & 18 others	60/100
9th	Miltenyi Biotec 1989, Bergisch Gladbach (Germany), Funding Raised	Develops tools and products for research and clinical application	-	Europa, HHS	58/100
10th	AlitheaGenomics 2020, Lausanne (Switzerland), Seed	Provider of transcriptomics solutions for research and biomarker discovery	$8.13M	Novalis Biotech, Zurcher Kantonalbank & 4 others	58/100
379th	RiboTask 2006, Langeskov (Denmark), Seed	Develops LNA-modified RNA oligonucleotides, RNAi and microRNA research applications;	-	Science Ventures	17/100